Specific protection against breast cancers by cyclin D1 ablation
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Breast cancer is the most common malignancy among women. Most of these cancers overexpress cyclin D1, a component of the core cell-cycle machinery. We previously generated mice lacking cyclin D1 using gene targeting. Here we report that these cyclin D1-deficient mice are resistant to breast cancers induced by the neu and ras oncogenes. However, animals lacking cyclin D1 remain fully sensitive to other oncogenic pathways of the mammary epithelium, such as those driven by c-myc or Wnt-1. Our analyses revealed that, in mammary epithelial cells, the Neu-Ras pathway is connected to the cell-cycle machinery by cyclin D1, explaining the absolute dependency on cyclin D1 for malignant transformation in this tissue. Our results suggest that an anti-cyclin D1 therapy might be highly specific in treating human breast cancers with activated Neu-Ras pathways.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“genetically engineered mouse models clearly revealed the importance of cyclin D1-CDK4 activity for the initiation and maintenance of HER2-driven breast cancers (98-100)”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [98]
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
β-Catenin regulates expression of cyclin D1 in colon carcinoma cells
Tetsu, O., & McCormick, F. (1999) · Nature · doi:10.1038/18884 · Cited by 3,601
Cyclin D1 Expression Is Regulated Positively by the p42/p44 and Negatively by the p38/HOG Pathway
Lavoie, J. N., L'Allemain, G., Brunet, A., Müller, R., & Pouysségur, J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.34.20608 · Cited by 1,211 · cited 1×
“Discussion The ras oncogene, acting through the mitogen-activated protein kinase pathway, is known to induce cyclin D1 by acting on cyclin D1 promote”
BackgroundMuller, W. J., Sinn, E., Pattengale, P. K., Wallace, R., & Leder, P. (1988) · Cell · doi:10.1016/0092-8674(88)90184-5 · Cited by 1,165
Cyclin D1 provides a link between development and oncogenesis in the retina and breast
Sicinski, P., Donaher, J. L., Parker, S. B., Li, T., Fazeli, A., Gardner, H., Haslam, S. Z., Bronson, R. T., Elledge, S. J., & Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90034-9 · Cited by 1,021
Bargmann, C. I., Hung, M.-C., & Weinberg, R. A. (1986) · Cell · doi:10.1016/0092-8674(86)90779-8 · Cited by 1,006
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
Wang, T. C., Cardiff, R. D., Zukerberg, L., Lees, E., Arnold, A., & Schmidt, E. V. (1994) · Nature · doi:10.1038/369669a0 · Cited by 965
Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes
Stewart, T. A., Pattengale, P. K., & Leder, P. (1984) · Cell · doi:10.1016/0092-8674(84)90257-5 · Cited by 899
Transforming p21 Mutants and c-Ets-2 Activate the Cyclin D1 Promoter through Distinguishable Regions
Albanese, C., Johnson, J., Watanabe, G., Eklund, N., Vu, D., Arnold, A., & Pestell, R. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.40.23589 · Cited by 803
Sinn, E., Muller, W., Pattengale, P., Tepler, I., Wallace, R., & Leder, P. (1987) · Cell · doi:10.1016/0092-8674(87)90449-1 · Cited by 792
Cited by
Items 301–400 of 937
Antitumor activity of HER-2 inhibitors
Rabindran, S. K. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.11.015 · Cited by 98
“[148] Q.”
BackgroundTransgenic Animal Models in Biomedical Research
Houdebine, L. (2006) · Humana Press eBooks · doi:10.1385/1-59745-165-7:163 · Cited by 123
Ahola, T. M., Manninen, T., Alkio, N., & Ylikomi, T. (2002) · Endocrinology · doi:10.1210/en.2001-211445 · Cited by 86
“Cyclin D1 has a causative role in breast cancer formation (24, 25), and it is overexpressed in several mammary carcinomas (26, 27).”
BackgroundLiu, J., Sun, X., Dong, H., Sun, C., Sun, W., Chen, B., Song, Y., & Yang, B. (2008) · International Journal of Cancer · doi:10.1002/ijc.23453 · Cited by 84
“These studies indicate that the induction of cyclin D1 degradation may offer a useful avenue for therapeutic intervention.(36) In this study, b-ionone has been observed to potently inhibit proliferative activity and to affect the cell cycle in mammary cancer cells.”
BackgroundMillar, E. K. A., Dean, J. L., McNeil, C. M., O'Toole, S. A., Henshall, S. M., Tran, T., Lin, J., Quong, A., Comstock, C. E. S., Witkiewicz, A., et al. (2009) · Oncogene · doi:10.1038/onc.2009.13 · Cited by 85
“Correspondingly, cyclin D1-null mice are refractory to mammary tumor development driven by multiple oncogenes (Yu et al., 2001), whereas the transgenic expression of cyclin D1 is sufficient to induce mammary tumors in mice (Wang et al.”
CDK4: a master regulator of the cell cycle and its role in cancer
Baker, S. J., Poulikakos, P. I., Irie, H. Y., Parekh, S. S., & Reddy, E. P. (2022) · Genes & Cancer · doi:10.18632/genesandcancer.221 · Cited by 91
“In this regard, CYCLIN D1 expression is up-regulated in tumors induced by Wnt-1 and c-Myc, but not by Neu or Ras [79].”
BackgroundInfluentialCreamer, B. A., Sakamoto, K., Schmidt, J. W., Triplett, A. A., Moriggl, R., & Wagner, K. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00851-09 · Cited by 96
“Since Stat5 regulates the expression of Akt1, as well as the functionality of cyclin D1 in mammary epithelial cells, the protective effect of Jak2 deficiency on mammary cancer initiation might be mediated by both or either one of these downstream targets, as previous studies indicate (7, 36, 54).”
ResultXiong, R., Zhao, J., Gutgesell, L. M., Wang, Y., Lee, S., Karumudi, B., Zhao, H., Lu, Y., Tonetti, D. A., & Thatcher, G. R. J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01355 · Cited by 110
FOXC1 in cancer development and therapy: deciphering its emerging and divergent roles
Yang, Z. P., Jiang, S., Cheng, Y., Li, T. X., Hu, W., Ma, Z., Chen, F., & Yang, Y. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017742576 · Cited by 85
Zhou, Q., Wang, X., Liu, X.-J., Zhang, H., Lu, Y.-Y., & Su, S. (2011) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.97 · Cited by 83
Chang, T.-H., & Szabo, E. M. (2002) · PubMed · Cited by 94
Modulation of Cell Cycle Components by Epigenetic and Genetic Events
Macaluso, M., Montanari, M., Cinti, C., & Giordano, A. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.07.009 · Cited by 95
Grillo, M., Bott, M. J., Khandke, N., McGinnis, J. P., Miranda, M., Meyyappan, M., Rosfjord, E. C., & Rabindran, S. K. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9066-y · Cited by 89
“Consistent with the central role of cyclin D1 in integrating growth factor-mediated signals to the cell cycle machinery, cyclin D1 knockout mice are resistant to tumorigenesis induced by HER-2 and Ras [55,56].”
BackgroundNotch Signaling and Breast Cancer
Reedijk, M. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0899-4_18 · Cited by 92
Jeyabalan, J., Aqil, F., Munagala, R., Annamalai, L., Vadhanam, M. V., & Gupta, R. C. (2013) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf403734j · Cited by 80
Wright, C. W., Rumble, J. M., & Duckett, C. S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608817200 · Cited by 97
Rodriguez-Mora, O. G., LaHair, M. M., McCubrey, J. A., & Franklin, R. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0271 · Cited by 65
“It was recently shown that cyclin D1 is essential for the development of mammary cancers induced by c-neu and v-Ha-ras (40).”
BackgroundHemizygous Disruption of Cdc25A Inhibits Cellular Transformation and Mammary Tumorigenesis in Mice
Ray, D., Terao, Y., Nimbalkar, D., Hirai, H., Osmundson, E. C., Zou, X., Franks, R. R., Christov, K. T., & Kiyokawa, H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4815 · Cited by 92
Impaired cell adhesion and apoptosis in a novel CLN9 Batten disease variant
Schulz, A., Dhar, S., Rylova, S. N., Dbaibo, G. S., Alroy, J., Hagel, C., Artacho, I., Kohlschütter, A., Lin, S. M., & Boustany, R. (2004) · Annals of Neurology · doi:10.1002/ana.20187 · Cited by 79
“Cyclin D1, a protooncogene involved in malignant transformation of breast tissue, was significantly downregulated, as was member 1A of the tumor necrosis factor receptor superfamily probably as a secondary response.(36) Gene expressions of multiple subunits of cytochrome c oxidase and of glutathione S–transferase A4 a…”
BackgroundWilliams, T. M., Sotgia, F., Lee, H., Hassan, G. S., Vizio, D. D., Bonuccelli, G., Capozza, F., Mercier, I., Rui, H., Pestell, R. G., et al. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.060590 · Cited by 86
“Furthermore, in mice, cyclin D1 expression is required for the oncogenic transformation of mammary epithelial cells by activated c-Neu/ErbB2.(31,44) Definitive proof of the importance of cyclin D1 in murine mammary tumorigenesis was demonstrated through the generation of MMTV-cyclin D1 mice.”
BackgroundRb and FZR1/Cdh1 determine CDK4/6-cyclin D requirement in C. elegans and human cancer cells
The, I., Ruijtenberg, S., Bouchet, B. P., Cristobal, A., Prinsen, M. B. W., van Mourik, T., Koreth, J., Xu, H., Heck, A. J. R., Akhmanova, A. S., et al. (2015) · Nature Communications · doi:10.1038/ncomms6906 · Cited by 88
MMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancer
Taneja, P., Frazier, D. P., Kendig, R. D., Maglic, D., Sugiyama, T., Kai, F., Taneja, N. K., & Inoue, K. (2009) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.09.31 · Cited by 104
Zeng, X., Shaikh, F. Y., Harrison, M. K., Adon, A. M., Trimboli, A. J., Carroll, K. A., Sharma, N., Timmers, C., Chodosh, L. A., Leone, G., et al. (2010) · Oncogene · doi:10.1038/onc.2010.253 · Cited by 78
“As ablation of cyclin D1 or Cdk4 abrogates mammary tumorigenesis in MMTV-Ras or MMTV-Neu (Her2) mice (Yu et al., 2001; Reddy et al., 2005), Cdk4/Cdk6-specific inhibitors reduce ectopic proliferation in human Her2+ breast cancer cells (Finn et al., 2009), and inhibitors of Nek2 decrease the…”
Imaging and Oncologic Drug Development
El‐Deiry, W. S., Sigman, C. C., & Kelloff, G. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.5623 · Cited by 82
“There are also tissue-specific knockouts of tumor suppressor genes such as BRCA1 or PTEN, among many others.92-94 Other transgenics include tissue-specific oncogene activation (eg, RAS activation in the lung or pancreas, with or without mutant p53 expression),95-99 or various oncogenes activated in the mammary gland,…”
BackgroundThe prolyl isomerase Pin1 in breast development and cancer
Wulf, G., Ryo, A., Liou, Y.-C., & Ping Lu, K. (2003) · Breast Cancer Research · doi:10.1186/bcr572 · Cited by 77
“It is of interest, however, that the mean Pin1 levels in estrogen-receptor-negative patients and in Her2/Neu-positive patients are, respectively, about twice and 1.7 times those in normal controls [34].”
InfluentialKhan, A., Aljarbou, A. N., Aldebasi, Y. H., Faisal, S. M., & Khan, M. A. (2014) · Cancer Epidemiology · doi:10.1016/j.canep.2014.09.006 · Cited by 81
“Noticeably, the decreased expression of cyclin D1 was observed as it is required for HER2 induced transformation and could reciprocally up-regulate HER2 expression [50,51].”
BackgroundExamining the Role of Cyclin D1 in Breast Cancer
Velasco-Velázquez, M. A., Li, Z., Casimiro, M. C., Loro, E., Homsi, N., & Pestell, R. G. (2011) · Future Oncology · doi:10.2217/fon.11.56 · Cited by 92
Sakamoto, K., Creamer, B. A., Triplett, A. A., & Wagner, K. (2007) · Molecular Endocrinology · doi:10.1210/me.2006-0316 · Cited by 84
The coupling of cell growth to the cell cycle
Tapon, N., Moberg, K. H., & Hariharan, I. K. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00284-2 · Cited by 79
Suchyta, S. P., Sipkovsky, S., Halgren, R. G., Kruska, R., Elftman, M. D., Weber-Nielsen, M., VandeHaar, M. J., Xiao, L., Tempelman, R. J., & Coussens, P. M. (2003) · Physiological Genomics · doi:10.1152/physiolgenomics.00028.2003 · Cited by 88
Jessen, K. A., English, N. M., Wang, J. Y., Maliartchouk, S., Archer, S. P., Qiu, L., Brand, R., Kuemmerle, J., Zhang, H., Gehlsen, K. R., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0333 · Cited by 75
Rajabi, H. N., Ahmad, R., Jin, C., Kosugi, M., Alam, M., Joshi, M. D., & Kufe, D. W. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.323311 · Cited by 83
“By contrast, cyclin D1 is dispensable for c-myc or Wnt-1-driven mammary tumorigenesis, indicating that cyclin D1 may be of importance in only certain types of breast cancer (35).”
BackgroundThe cyclin D1b splice variant: an old oncogene learns new tricks.
Knudsen, K. E. (2006) · Cell Division · doi:10.1186/1747-1028-1-15 · Cited by 93
“pancreatic and breast cancer) [53-55], and how the disparate functions of cyclin D1b may influence outcome should likely be incorporated as a major consideration.”
BackgroundHu, Z., Chen, J., Zhou, S., Yang, N., Duan, S., Zhang, Z., Su, J., He, J., Zhang, Z., Lü, X., et al. (2017) · Theranostics · doi:10.7150/thno.16236 · Cited by 75
“It is well established that defects in cell cycle and apoptosis underlie the loss of control of cell growth leading to the development and progression of tumors [29, 30].”
BackgroundRodríguez‐Puebla, M. L., de Marval, P. L. M., LaCava, M., Moons, D. S., Kiyokawa, H., & Conti, C. J. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64196-x · Cited by 86
Tsou, H., Liu, X., Birnberg, G. H., Kaplan, J. A., Otteng, M., Tran, T., Kutterer, K. M. K., Tang, Z., Suayan, R., Zask, A., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801026e · Cited by 81
CDC25A Phosphatase: a Rate-Limiting Oncogene That Determines Genomic Stability
Ray, D., & Kiyokawa, H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5983 · Cited by 75
Liver receptor homolog-1 (LRH-1): a potential therapeutic target for cancer
Nadolny, C., & Dong, X. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1045693 · Cited by 81
“It is also frequently overexpressed in gastrointestinal tumors(19,91,95) and promotes tumor formation in vivo.(96) Based on the synergy between b-catenin and LRH-1 signaling, LRH-1 is proposed to contribute to gastrointestinal tumorigenesis.”
BackgroundShee, K., Yang, W., Hinds, J. W., Hampsch, R. A., Varn, F. S., Traphagen, N. A., Patel, K., Cheng, C., Jenkins, N. P., Kettenbach, A. N., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171818 · Cited by 73
Yoshida, K., Matsuzaki, K., Murata, M., Yamaguchi, T., Suwa, K., & Okazaki, K. (2018) · Cancers · doi:10.3390/cancers10060183 · Cited by 73
“Cyclin D knockout mice are protected from Ras-induced cancers [50].”
BackgroundTranslating basic cancer research into new cancer therapeutics
Workman, P., & Kaye, S. B. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02319-5 · Cited by 79
Cell cycle, proteolysis and cancer
Yamasaki, L., & Pagano, M. (2004) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2004.08.005 · Cited by 83
“Mice expressing Cyclin D1 in the mammary epithelium develop mammary hyperplasia and mammary carcinomas at low penetrance [4], while mice lacking Cyclin D1 (Ccnd1 / ) are resistant to breast tumors induced by the neu or Ras oncogenes [5].”
BackgroundRas and Myc can drive oncogenic cell proliferation through individual D-cyclins
Yu, Q., Ciemerych, M. A., & Siciński, P. (2005) · Oncogene · doi:10.1038/sj.onc.1208853 · Cited by 80
“On the other hand, cyclin D1-null mice remained susceptible to Ras-driven salivary gland tumors, while cyclin D1 / MEFs were susceptible to the malignant transformation by the oncogenic Ras (Yu et al., 2001).”
BackgroundInfluentialSelf-citationC/EBPδ targets cyclin D1 for proteasome-mediated degradation via induction of CDC27/APC3 expression
Pawar, S. A., Sarkar, T. R., Balamurugan, K., Sharan, S., Wang, J., Zhang, Y., Dowdy, S. F., Huang, A., & Sterneck, E. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913813107 · Cited by 86
“In contrast to C/EBPδ, cyclin D1 is highly expressed in >50% of breast tumors (13), and mouse models have established cyclin D1 as a key driver of mammary oncogenesis (14, 15).”
BackgroundLam, P. B., Burga, L. N., Wu, B. P., Hofstatter, E. W., Lu, K. P., & Wulf, G. M. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-91 · Cited by 73
“Pin1 is a pivotal regulator of cyclin D1 expression [7,8,13,14,25], and disruption of the cyclin D1 gene in mice also suppresses the ability of the c-Neu transgene to induce tumor development in the mammary gland [26].”
BackgroundYang, C., Trent, S., Ionescu-Tiba, V., Lan, L., Shioda, T., Sgroi, D. C., & Schmidt, E. V. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1645 · Cited by 78
Stem/Progenitor Cells in Mouse Mammary Gland Development and Breast Cancer
Li, Y., & Rosen, J. M. (2005) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-005-2537-2 · Cited by 73
Mitchell, D., Abdelrahim, M., Weng, J., Stafford, L. J., Safe, S. H., Bar‐Eli, M., & Liu, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506245200 · Cited by 78
Wikman, H., & Kettunen, E. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.4.515 · Cited by 72
Rearrangements and increased expression of cyclin D1 (CCND1) in neuroblastoma
Molenaar, J. J., Sluis, P. V., Boon, K., Versteeg, R., & Caron, H. N. (2003) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10166 · Cited by 82
Expression of cyclins E1 and E2 during mouse development and in neoplasia
Geng, Y., Yu, Q., Whoriskey, W., Dick, F. A., Tsai, K. Y., Ford, H. L., Biswas, D. K., Pardee, A. B., Amati, B. B., Jacks, T., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231487798 · Cited by 84
Self-citationBarton, B. E., Karras, J. G., Murphy, T. F., Barton, A., & Huang, H. F.-S. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.11.3.1 · Cited by 72
Boulon, S., Dantonel, J.-C., Binet, V., Vié, A., Blanchard, J., Hipskind, R. A., & Philips, A. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.22.7769-7779.2002 · Cited by 76
“This appears to be directly linked to Ras signaling, since mice bearing a disrupted cyclin D1 locus are resistant to breast cancers induced by the neu and ras oncogenes (55).”
BackgroundSmad3 phosphorylation by cyclin-dependent kinases
LIU, F. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.09.010 · Cited by 71
“For example, mice lacking cyclin D1 are resistant to Ras- or Neu-induced breast cancer [74].”
BackgroundCyclin-Dependent Kinase Modulators and Cancer Therapy
Gallorini, M., Cataldi, A., & di Giacomo, V. (2012) · BioDrugs · doi:10.1007/bf03261895 · Cited by 82
“In most kinds of cancers, CDKN2A is downregulated by gene deletion, point mutation, or transcriptional silencing by methylation,([56]) therefore cancer cells grow uncontrollably by increasing their D-cyclin intracellular levels.”
BackgroundCDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review
Vinciguerra, G. L. R., Sonego, M., Segatto, I., Dall’Acqua, A., Vecchione, A. M., Baldassarre, G., & Belletti, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.891580 · Cited by 82
“Palbociclib Wee-1 inhibitor Adavosertib HR+ breast cancer apoptosis of G2 checkpoint dependent cells (54)”
BackgroundEstrogen Regulation of Cyclin E2 Requires Cyclin D1 but Not c-Myc
Caldon, C. E., Sergio, C. M., Schütte, J., Boersma, M. N., Sutherland, R. L., Carroll, J. S., & Musgrove, E. A. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00269-09 · Cited by 83
“, who identified high levels of cyclin E1 and cyclin E2 mRNAs in c-Myc-driven mouse mammary tumors but low levels of both transcripts in Ras-driven tumors (27), which commonly display increased levels of cyclin D1 and are dependent on cyclin D1 (75).”
BackgroundYde, C. W., & Issinger, O. (2006) · International Journal of Oncology · doi:10.3892/ijo.29.6.1397 · Cited by 82
Pointed and Tramtrack69 establish an EGFR-dependent transcriptional switch to regulate mitosis
Baonza, A., Murawsky, C. M., TRAVERS, A. A., & Freeman, M. (2002) · Nature Cell Biology · doi:10.1038/ncb887 · Cited by 77
Mendoza, N., Fong, S., Marsters, J., Koeppen, H., SCHWALL, R. H., & Wickramasinghe, D. (2003) · PubMed · Cited by 83
Cross signaling, cell specificity, and physiology
Dumont, J. E., Dremier, S., Pirson, I., & Maenhaut, C. (2002) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00581.2001 · Cited by 73
Lebeau, A., Unholzer, A., Amann, G., Kronawitter, M., Bauerfeind, I., Sendelhofert, A., Iff, A., & Löhrs, U. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1023958324448 · Cited by 72
Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia
Follini, E., Marchesini, M., & Roti, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20123021 · Cited by 81
“In addition, D cyclins are required for tumor initiation, as mice lacking cyclin D1 are resistant to ErbB2-driven mammary adenocarcinomas [145,148], while cyclin D3 null animals are refractory to Notch1-driven T-ALL [147].”
BackgroundTimms, J. F., White, S. L., O’Hare, M. J., & Waterfield, M. D. (2002) · Oncogene · doi:10.1038/sj.onc.1205847 · Cited by 70
“More importantly, cyclin D1 was recently shown to be necessary for both activated ErbB-2 and Ras-induced malignant transformation of murine mammary epithelial cells (Yu et al., 2001).”
BackgroundKonopleva, M. Y., Zhang, W., Shi, Y.-X., McQueen, T. J., Tsao, T., Abdelrahim, M., Munsell, M. F., Johansen, M. J., Yu, D., Madden, T. L., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0350 · Cited by 70
“for the development of HER2/neu- or Ras-induced breast cancers (44).”
BackgroundPhospho-specific Smad3 signaling: Impact on breast oncogenesis
Tarasewicz, E., & Jeruss, J. S. (2012) · Cell Cycle · doi:10.4161/cc.20546 · Cited by 76
CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure
Garrido-Castro, A. C., & Goel, S. (2017) · Current Breast Cancer Reports · doi:10.1007/s12609-017-0232-0 · Cited by 69
“In an elegant study, Yu and colleagues demonstrated that cyclin D1 knockout mice are completely resistant to the formation of breast cancers induced either by the Erbb2 or Ras oncogenes [4].”
BackgroundAutophagy and Breast Cancer: Connected in Growth, Progression, and Therapy
Wu, Q., & Sharma, D. (2023) · Cells · doi:10.3390/cells12081156 · Cited by 79
Barton, B. E. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.4.737 · Cited by 80
“Because activated STAT3 is associated with many types of solid tumours, including breast, squamous cell, melanoma and others [46,121-126], it is possible that IL-6 is also Table 1.”
BackgroundDisruption of cyclin D1 nuclear export and proteolysis accelerates mammary carcinogenesis
Lin, D. I., Lessie, M. D., Gladden, A. B., Bassing, C. H., Wagner, K., & Diehl, J. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210738 · Cited by 73
“Additionally, cyclin D1 null mice are resistant to mammary tumorigenesis induced by erbB2 and Ras, revealing a requirement for cyclin D1 downstream of these oncogenes (Yu et al., 2001).”
BackgroundBerrak, Ö., Akkoç, Y., Arısan, E. D., Gürkan, A. Ç., Yerlikaya, P. O., & Palavan-Ünsal, N. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.12.007 · Cited by 72
Liu, Y., Lu, C., Shen, Q., Munoz‐Medellin, D., Kim, H., & Brown, P. H. (2004) · Oncogene · doi:10.1038/sj.onc.1207889 · Cited by 69
“In breast cancer, cyclin E also drives proliferation (Yu et al., 2001), its overexpression is a negative prognostic factor (Nielsen et al., 1996) and an independent risk factor of visceral relapse in breast cancer (Kim et al., 2001).”
BackgroundKampfer, S., Windegger, M., Hochholdinger, F., Schwaiger, W., Pestell, R. G., Baier, G., Grunicke, H. H., & Überall, F. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102047200 · Cited by 71
Ling, H., Sylvestre, J.-R., & Jolicoeur, P. (2010) · Oncogene · doi:10.1038/onc.2010.186 · Cited by 75
Gu, W., Pan, F., & Singer, R. H. (2009) · Journal of Cell Science · doi:10.1242/jcs.045278 · Cited by 80
“…breast-cancer cell lines: a rat non-metastatic MTC line, a human non-metastatic T47D cell line; two human MDA435 and MDA231 cell lines, both of which have been identified as highly invasive and metastatic (Zajchowski et al., 2001); and a mouse metastatic 4T1 cell line (Lelekakis et al., 1999).”
BackgroundGenetic Manipulation of the IGF-I Axis to Regulate Mammary Gland Development and Function
Hadsell, D. L., Bonnette, S. G., & Lee, A. V. (2002) · Journal of Dairy Science · doi:10.3168/jds.s0022-0302(02)74083-6 · Cited by 77
“Noteworthy examples of success with this type of approach (Guy et al., 1996; Hutchinson et al., 2001; Yu et al., 2001) serve as indicators that much can be learned from the Igflr -/- graft model about the regulation of mammary gland development by IGF-I.”
BackgroundNakshatri, H., & Goulet, R. J. (2002) · Current Problems in Cancer · doi:10.1067/mcn.2002.129977 · Cited by 78
An antisense oligodeoxynucleotide to p21(Waf1/Cip1) causes apoptosis in human breast cancer cells.
Fan, Y., Borowsky, A. D., & Weiss, R. H. (2003) · PubMed · Cited by 74
HER2/Neu tumorigenesis and metastasis is regulated by E2F activator transcription factors
Andrechek, E. R. (2013) · Oncogene · doi:10.1038/onc.2013.540 · Cited by 72
“is essential for Neu mediated tumors (12), the importance of the combination of E2F alleles becomes apparent.”
InfluentialCyclin D1 is necessary for tamoxifen-induced cell cycle progression in human breast cancer cells.
Kilker, R. L., & Planas-Silva, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1755 · Cited by 62
The Contributions of HIF-Target Genes to Tumor Growth in RCC
Zhang, T., Niu, X., Liao, L., Cho, E.-A., & Yang, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080544 · Cited by 75
“Cyclin D1 is a very important cell cycle regulator and is reported to be oncogenic in breast cancer [25], and it was also reported to be a faithful target of HIF2α that might play an important role in kidney cancer [26].”
BackgroundShah, N. G., Trivedi, T. I., Tankshali, R. A., Goswami, J., Shah, J., Jetly, D., Kobawala, T. P., Patel, K. C., Shukla, S. N., Shah, P. M., et al. (2007) · The International Journal of Biological Markers · doi:10.5301/jbm.2008.4745 · Cited by 73
Singh, K., Mogare, D., Giridharagopalan, R. O., Gogiraju, R., Pande, G., & Chattopadhyay, S. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000660 · Cited by 69
“Among all Cyclins, Cyclin D1 expression is one of the hallmarks of breast cancer progression and is considered as a positive diagnostic marker [11,12].”
BackgroundTognon, C. E., Somasiri, A. M., Evdokimova, V. E., Trigo, G., Uy, E. E., Melnyk, N., Carboni, J. M., Gottardis, M. M., Roskelley, C. D., Pollak, M., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3096 · Cited by 67
Rho GTPases as Key Transducers of Proliferative Signals in G1 Cell Cycle Regulation
Welsh, C. F. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000018425.31633.07 · Cited by 77
“Significantly, studies of tumor formation in cyclin D1-null mice further indicate that cyclin D1 is essential for mammary carcinogenesis specifically induced by expression of the neu or Ras oncogenes [71].”
BackgroundWang, Y., Dean, J. L., Millar, E. K. A., Tran, T. H., McNeil, C. M., Burd, C. J., Henshall, S. M., Utama, F. E., Witkiewicz, A., Rui, H., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3170 · Cited by 66
“protects against mammary tumorigenesis (12, 13).”
Zelivianski, S., Cooley, A. E., Kall, R., & Jeruss, J. S. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0537 · Cited by 72
Rho regulates p21CIP1, cyclin D1, and checkpoint control in mammary epithelial cells
Liberto, M., Cobrinik, D. E., & Minden, A. (2002) · Oncogene · doi:10.1038/sj.onc.1205242 · Cited by 68
“…D1 expression may have substantial relevance to mammary tumorigenesis, since cyclin D1 is over-expressed in at least 50% of human mammary carcinomas (Bartkova et al., 1994; Gillett et al., 1994), and is required for oncogenic Neu and Ras-induced mammary tumorigenesis in mice (Yu et al., 2001).”
BackgroundPatterns of gene amplification in gastrointestinal stromal tumors (GIST)
Tornillo, L., Duchini, G., Carafa, V., Lugli, A., Dirnhofer, S., Vizio, D. D., Boscaino, A., Russo, R., Tapia, C., Schneider‐Stock, R., et al. (2005) · Laboratory Investigation · doi:10.1038/labinvest.3700284 · Cited by 68
“CCND1 amplification may have additional importance as CCND1 has been shown to be essential for malignant transformation in mammary epithelial cells”
BackgroundPotential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer
Hu, Y., Gao, J., Wang, M., & Li, M. (2021) · Cancer Management and Research · doi:10.2147/cmar.s310649 · Cited by 71
“The cell-cycle regulatory proteins CDK4 and CDK6 were identified in the early 1990s, and therapies targeting these proteins have since been developed, based on a large body of research demonstrating that overactivity of the cyclin D–CDK4/6 axis leads to excessive proliferation in tumor cells.(12,13) CDK4/6 kinases and…”
BackgroundWiedemeyer, W. R., Beach, J. A., & Karlan, B. Y. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00034 · Cited by 71
Chen, C., Hsu, Y., Chen, Y., Hung, J., Huang, M., & Kuo, P. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.07.028 · Cited by 66
Xie, Z., Zeng, X., Waldman, T. A., & Glazer, R. I. (2003) · PubMed · Cited by 73
Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA
Pérez, M., Muñoz-Galván, S., Jiménez-García, M. P., Marín, J., & Carnero, A. (2015) · Oncotarget · doi:10.18632/oncotarget.5829 · Cited by 71
“Mice lacking cyclin D1 were refractory to mammary tumor development induced by the ErbB2 oncogene, the ortholog of HER2, which is frequently overexpressed in human breast carcinomas [19, 24, 25].”
Bisi, J., Sorrentino, J. A., Jordan, J. L., Darr, D. D., Roberts, P. J., Tavares, F. X., & Strum, J. C. (2017) · Oncotarget · doi:10.18632/oncotarget.16216 · Cited by 65
“Additionally, many of the receptor-mediated growth pathways that are activated in human cancers increase D-type-cyclin transcription and expression to drive cellular proliferation [16, 17].”
BackgroundDragnev, K. H., Pitha, I., Ma, Y., Petty, W. J., Sekula, D., O’Sullivan-Murphy, B., Rendi, M. H., Suh, N., Desai, N. B., Sporn, M. B., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0271 · Cited by 64
“Cyclin D1 is an attractive target to consider, because engineered transgenic models indicate its important role in carcinogenesis (41).”
BackgroundShimazaki, R., Takano, S., Satoh, M., Takada, M., Miyahara, Y., Sasaki, K., Yoshitomi, H., Kagawa, S., Furukawa, K., Takayashiki, T., et al. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00614-z · Cited by 67
Cyclin D1 Represses Gluconeogenesis via Inhibition of the Transcriptional Coactivator PGC1α
Bhalla, K., Liu, W.-J., Thompson, K. N., Anders, L., Devarakonda, S., Dewi, R. E., Buckley, S., Hwang, B., Polster, B. M., Dorsey, S. G., et al. (2014) · Diabetes · doi:10.2337/db13-1283 · Cited by 66
“Cyclin d1 and Cyclin d1 mice have been described previously (41,42).”
BackgroundBowe, D. B., Kenney, N. J., Adereth, Y., & Maroulakou, I. G. (2002) · Oncogene · doi:10.1038/sj.onc.1205025 · Cited by 61
“In addition, data from this manuscript (Figure 5b), and a recent publication (Yu et al., 2001), indicate that epithelial cells express the MMTV-transgene independently of cyclin D1 genotype.”
BackgroundInfluentialChemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows
Roberts, P. J., Kumarasamy, V. M., Witkiewicz, A. K., & Knudsen, E. S. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1161 · Cited by 66
Metadata
- Authors
- Yu, Q., Geng, Y., & Sicinski, P.
- Affiliations
- Harvard University (US)
- ORCID
- Yu, Qunyan
- Venue
- Nature
- Published
- 2001-06
- Volume
- 411
- Issue
- 6841
- Pages
- 1017-1021
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2098953839
- Cited by
- 934
- References
- 31
- Citations by year
- 2026: 9 · 2025: 5 · 2024: 12 · 2023: 26 · 2022: 19 · 2021: 24 · 2020: 32 · 2019: 22 · 2018: 24 · 2017: 36 · 2016: 25 · 2015: 33 · 2014: 32 · 2013: 33 · 2012: 35
- FWCI
- 33.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- cyclin D1, breast cancer, neu oncogene, oncogenic Ras, cell cycle, mammary epithelium, malignant transformation, c-Myc, Wnt1, targeted cancer therapy
- MeSH terms
- Animals, Antineoplastic Agents, Breast, Breast Neoplasms, Cell Transformation, Neoplastic, Crosses, Genetic, Female, Humans, Male, Mammary Tumor Virus, Mouse, Mammary Neoplasms, Experimental, Proto-Oncogene Proteins, Genes, ras, Tumor Cells, Cultured, Genes, myc, Genes, erbB-2, Cyclin D1, Genes, bcl-1, Genetic Predisposition to Disease, Zebrafish Proteins, Animals, Genetically Modified, Wnt Proteins, Wnt1 Protein, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.